HRP20171236T1 - Upotreba prolijekova kanabidiola u topičkoj i transdermalnoj primjeni s mikroiglama - Google Patents

Upotreba prolijekova kanabidiola u topičkoj i transdermalnoj primjeni s mikroiglama Download PDF

Info

Publication number
HRP20171236T1
HRP20171236T1 HRP20171236TT HRP20171236T HRP20171236T1 HR P20171236 T1 HRP20171236 T1 HR P20171236T1 HR P20171236T T HRP20171236T T HR P20171236TT HR P20171236 T HRP20171236 T HR P20171236T HR P20171236 T1 HRP20171236 T1 HR P20171236T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
administration
hours
microneedles
group
Prior art date
Application number
HRP20171236TT
Other languages
English (en)
Inventor
Audra Lynn Stinchcomb
Stan Lee Banks
Miroslaw Jerzy Golinski
Jeffrey Lynn Howard
Dana Carmel Hammell
Original Assignee
Zynerba Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals, Inc. filed Critical Zynerba Pharmaceuticals, Inc.
Publication of HRP20171236T1 publication Critical patent/HRP20171236T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/16—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)

Claims (14)

1. Sustav s mikroiglama za isporuku lijeka za transdermalnu ili topičku primjenu predlijeka kanabidiola kod sisavca, naznačen time, da sadržava: a) farmaceutski pripravak koji sadržava predlijek kanabidiola koji ima formulu: [image] Pri čemu je X- protuion izveden iz farmaceutski prihvatljivih kiselina, i b) niz mikroigala, pri čemu je farmaceutski pripravak namijenjen za primjenu na kožu sisavca povezan s nizom mikroigala, bilo prije davanja nizom mikroigala, nakon davanja nizom mikroigala ili istovremeno s davanjem nizom mikroigala.
2. Sustav za primjenu lijeka u skladu s patentnim zahtjevom 1, naznačen time, da je predlijek kanabidiola prisutan u količini od oko 0,1 % do oko 50 % (težinski), oko 1 % do oko 40 % (tež. / tež.), oko 5 % do oko 30 % (tež. / tež.) ili oko 10 % do oko 20 % (tež. / tež.) farmaceutskog pripravka.
3. Sustav za primjenu lijeka u skladu s patentnim zahtjevom 1, naznačen time, da je farmaceutski pripravak u obliku hidrogela, poželjno je da je hidrogel ugrađen u naljepke tipa matrice ili rezervoara.
4. Sustav za primjenu lijeka u skladu sa zahtjevom 1, naznačen time, da farmaceutski pripravak nadalje sadrži inhibitor COX bira iz skupine koju čine: aspirin, diklofenak, diflunisal, fenoprofen, flurbiprofen, ibuprofen, indometacin, ketoprofen, ketorolak, mefenaminska kiselina, meloksikam, nabumeton naproksen, olsalzin, oksaprozin, piroksikam, salsalat, sulfasalazin, sulindak, tolmetin, mofezolak, SC-560, FR 122047, etodolak, celekoksib, rofekoksib, valdekoksib, parekoksib, lumirakoksib i etorikoksib.
5. Sustav za primjenu lijeka u skladu sa zahtjevom 1, naznačen time, da farmaceutski pripravak nadalje sadrži pojačivač prodiranja koji je odabran iz skupine koja se sastoji od sljedećeg: izostearinska kiselina, oktanoična kiselina, oleinska kiselina, oleil alkohol, lauril alkohol, etil-oleat, izopropil miristat, butil stearat, metil laurat, diizopropil adipat, gliceril monolaurat, tetrahidrofurfuril alkohol polietilen glikol eter, polietilen glikol, propilen glikol, 2-(2-etoksietoksi) etanol, dietilen glikol monometil eter, alkilaril eteri polietilen oksida, polietilen oksida monometil etera, polietilen oksid dimetil etera, dimetilsulfoksid, glicerol, ester acetooctene kiseline, N- alkil-pirolidon, terpeni, noktanol, natrijev oleat, D-limonen, monoolein, cineol, oleil oleat, etanol, propanol, butanol, 2-butanol, pentanol, 2-pentanol, heksanol, oktanol, nonanol, dekanol, benzil alkohol, Poliksamer 231, Poliksamer 182, Poliksamer 184, Polisorbat 20, Polisorbat 60, Brij 30, Brij 93, Brij 96, Brij 99, Span 20, Span 40, Span 60, Span 80, Span 85, Tween 20, Tween 40, Tween 60, Tween 80, Myrj 45, Myrj 51, Myrj 52 i Miglyol 840, pri čemu je poželjno da promotor prolaska bude prisutan u količini od oko 0,1 % do oko 40 % (tež. / tež.), oko 0,1 % do oko 30 % (tež. / tež.), oko 1 % do oko 20 % (tež. / tež.) ili od 1 % do oko 10 % (tež. / tež.) farmaceutskog pripravka.
6. Sustav za primjenu lijeka prema zahtjevu 1, naznačen time, da farmaceutski pripravak nadalje sadrži niži alkohol odabran iz skupine koju čine: etanol i izopropanol.
7. Sustav za primjenu lijeka u skladu s patentnim zahtjevom 1, naznačen time, da farmaceutski pripravak daje terapeutski učinkovitu količinu predlijeka kanabidiola tijekom vremenskog razdoblja odabranog iz skupine koju čine: oko 1 sat, oko 2 sata, oko 3 sata, oko 4 sata, oko 6 sati, oko 12 sati, oko 24 sata, oko 48 sati, oko 72 sata, oko 96 sati, oko 5 dana, oko 6 dana ili oko 7 dana.
8. Sustav s mikroiglama za isporuku lijeka u skladu s bilo kojim od zahtjeva 1 do 7, naznačen time, da je bolesno stanje odabrano iz skupine koju čine: akutni pankreatitis, kronični pankreatitis, rak gušterače, mučnina, povraćanje, bol, sindrom propadanja, propadanje uzrokovano HIV-om, kemoterapijom izazvane mučnine i povraćanja, poremećaji zbog upotrebe alkohola, distonija, multipla skleroza, upalne crijevne bolesti, artritis, dermatitis, reumatoidni artritis, sistemski eritematozni lupus, melanom, periferna neuropatska bol, neuropatska bol povezana s post- herpetičkom neuralgijom, dijabetička neuropatija, crvenilo, opekline, aktinska keratoza, rane i čirevi u usnoj šupljini, bol nakon epiziotomije, psorijaza, svrbež, kontaktni dermatitis, ekcem, bulozni dermatitis herpetiformis, eksfolijativni dermatitis, mycosis fungoides, pemfigus, teški multiformni eritem (npr. Stevens- Johnsonov sindrom), seboreični dermatitis, ankilozantni spondilitis, psorijatični artritis, Reiterov sindrom, giht, hondrokalcinoza, bol u zglobovima nakon dismenoreje, fibromijalgija, mišićno-koštana bol, neuropatske postoperativne komplikacije, polimiozitis, akutni nespecifični tenosinovitis, bursitis, epikondilitis, posttraumatski osteoartritis, osteoartritis, reumatoidni artritis, sinovitis, juvenilni reumatoidni artritis i inhibicija rasta dlačica.
9. Sustav za primjenu lijeka prema zahtjevu 1, naznačen time, da farmaceutski pripravak sadržava i. oko 0,1 % do oko 40 % predlijeka kanabidiola, ii. oko 0,1 % do oko 20 % jednog ili više kootapala, iii. oko 15 % do oko 95 % nižeg alkohola i iv. vodu u količini dovoljnoj da pripravak dostigne do 100 % (tež. / tež.).
10. Sustav za primjenu lijeka prema zahtjevu 9, naznačen time, da je predlijek kanabidiola prisutan u količini od oko 5 % do oko 30 % (tež. / tež.) ili oko 10 % do oko 20 % (tež. / tež.) farmaceutskog pripravka.
11. Sustav za primjenu lijeka prema zahtjevu 9, naznačen time, da je svako od kootapala odabrano iz skupine koju čine: etanol, benzil alkohol i njihove smjese.
12. Sustav za primjenu lijeka prema zahtjevu 9, naznačen time, da je farmaceutski pripravak u obliku hidrogela, poželjno je da je hidrogel ugrađen u matricu ili naljepak sa spremnikom.
13. Sustav za primjenu lijeka prema zahtjevu 9, naznačen time, da farmaceutski pripravak nadalje sadrži inhibitor COX odabran iz skupine koju čine: nespecifični inhibitor COX, inhibitor COX-1 i inhibitor COX-2.
14. Spoj, naznačen time, da je to spoj odabran iz skupine koju čine: [image] i pri čemu je X- protuion izveden iz farmaceutski prihvatljivih kiselin
HRP20171236TT 2009-08-31 2017-08-11 Upotreba prolijekova kanabidiola u topičkoj i transdermalnoj primjeni s mikroiglama HRP20171236T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23852409P 2009-08-31 2009-08-31
EP10755265.5A EP2473475B1 (en) 2009-08-31 2010-08-31 Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
PCT/US2010/047408 WO2011026144A1 (en) 2009-08-31 2010-08-31 Use of cannabidiol prodrugs in topical and transdermal administration with microneedles

Publications (1)

Publication Number Publication Date
HRP20171236T1 true HRP20171236T1 (hr) 2017-10-20

Family

ID=43469376

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171236TT HRP20171236T1 (hr) 2009-08-31 2017-08-11 Upotreba prolijekova kanabidiola u topičkoj i transdermalnoj primjeni s mikroiglama

Country Status (14)

Country Link
US (3) US20110052694A1 (hr)
EP (1) EP2473475B1 (hr)
JP (1) JP2013503206A (hr)
CA (1) CA2772634C (hr)
CY (1) CY1119059T1 (hr)
DK (1) DK2473475T3 (hr)
ES (1) ES2635084T3 (hr)
HR (1) HRP20171236T1 (hr)
HU (1) HUE034235T2 (hr)
LT (1) LT2473475T (hr)
PL (1) PL2473475T3 (hr)
PT (1) PT2473475T (hr)
SI (1) SI2473475T1 (hr)
WO (1) WO2011026144A1 (hr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784336B2 (en) 2005-08-24 2014-07-22 C. R. Bard, Inc. Stylet apparatuses and methods of manufacture
US8388546B2 (en) 2006-10-23 2013-03-05 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US7794407B2 (en) 2006-10-23 2010-09-14 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US8849382B2 (en) 2007-11-26 2014-09-30 C. R. Bard, Inc. Apparatus and display methods relating to intravascular placement of a catheter
US8781555B2 (en) 2007-11-26 2014-07-15 C. R. Bard, Inc. System for placement of a catheter including a signal-generating stylet
US10751509B2 (en) 2007-11-26 2020-08-25 C. R. Bard, Inc. Iconic representations for guidance of an indwelling medical device
US10524691B2 (en) 2007-11-26 2020-01-07 C. R. Bard, Inc. Needle assembly including an aligned magnetic element
US10449330B2 (en) 2007-11-26 2019-10-22 C. R. Bard, Inc. Magnetic element-equipped needle assemblies
ES2651898T3 (es) 2007-11-26 2018-01-30 C.R. Bard Inc. Sistema integrado para la colocación intravascular de un catéter
US9649048B2 (en) 2007-11-26 2017-05-16 C. R. Bard, Inc. Systems and methods for breaching a sterile field for intravascular placement of a catheter
US9521961B2 (en) 2007-11-26 2016-12-20 C. R. Bard, Inc. Systems and methods for guiding a medical instrument
US8478382B2 (en) 2008-02-11 2013-07-02 C. R. Bard, Inc. Systems and methods for positioning a catheter
US9901714B2 (en) 2008-08-22 2018-02-27 C. R. Bard, Inc. Catheter assembly including ECG sensor and magnetic assemblies
US8437833B2 (en) 2008-10-07 2013-05-07 Bard Access Systems, Inc. Percutaneous magnetic gastrostomy
US9445734B2 (en) 2009-06-12 2016-09-20 Bard Access Systems, Inc. Devices and methods for endovascular electrography
JP5795576B2 (ja) 2009-06-12 2015-10-14 バード・アクセス・システムズ，インコーポレーテッド 心電図（ｅｃｇ）信号を使用して心臓内またはその近くに血管内デバイスを位置決めするコンピュータベースの医療機器の作動方法
US9532724B2 (en) 2009-06-12 2017-01-03 Bard Access Systems, Inc. Apparatus and method for catheter navigation using endovascular energy mapping
US20110052694A1 (en) * 2009-08-31 2011-03-03 Alltranz Inc. Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
AU2010300677B2 (en) 2009-09-29 2014-09-04 C.R. Bard, Inc. Stylets for use with apparatus for intravascular placement of a catheter
WO2011044421A1 (en) 2009-10-08 2011-04-14 C. R. Bard, Inc. Spacers for use with an ultrasound probe
BR112012019354B1 (pt) 2010-02-02 2021-09-08 C.R.Bard, Inc Método para localização de um dispositivo médico implantável
WO2011150376A1 (en) 2010-05-28 2011-12-01 C.R. Bard, Inc. Apparatus for use with needle insertion guidance system
ES2864665T3 (es) 2010-05-28 2021-10-14 Bard Inc C R Aparato para su uso con sistema de guiado de inserción de aguja
JP2013535301A (ja) 2010-08-09 2013-09-12 シー・アール・バード・インコーポレーテッド 超音波プローブヘッド用支持・カバー構造
JP5845260B2 (ja) 2010-08-20 2016-01-20 シー・アール・バード・インコーポレーテッドＣ Ｒ Ｂａｒｄ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｅｃｇ支援カテーテル先端配置の再確認
WO2012058461A1 (en) 2010-10-29 2012-05-03 C.R.Bard, Inc. Bioimpedance-assisted placement of a medical device
US9566341B1 (en) 2011-04-27 2017-02-14 University Of Kentucky Research Foundation Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same
RU2609203C2 (ru) 2011-07-06 2017-01-30 Си.Ар. Бард, Инк. Определение и калибровка длины иглы для системы наведения иглы
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
USD724745S1 (en) 2011-08-09 2015-03-17 C. R. Bard, Inc. Cap for an ultrasound probe
WO2013070775A1 (en) 2011-11-07 2013-05-16 C.R. Bard, Inc Ruggedized ultrasound hydrogel insert
ES2692663T3 (es) * 2011-12-26 2018-12-04 Tritech Biopharmaceuticals Co. Ltd. Método y composición farmacéutica mejorada para mejorar la entrega transdérmica del inhibidor PDE-5
CN103301092B (zh) * 2012-03-06 2014-12-03 中国科学院理化技术研究所 聚合物微针阵列芯片及其制备方法和应用
EP2861153A4 (en) 2012-06-15 2016-10-19 Bard Inc C R APPARATUS AND METHODS FOR DETECTION OF A REMOVABLE CAP ON AN ULTRASONIC PROBE
CA2935899C (en) 2013-01-08 2021-08-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Fluorinated cbd compounds, compositions and uses thereof
GB2517707B (en) 2013-08-28 2020-09-02 Pci Biotech As A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen
WO2015120256A2 (en) 2014-02-06 2015-08-13 C.R. Bard, Inc. Systems and methods for guidance and placement of an intravascular device
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US20150324942A1 (en) * 2014-05-09 2015-11-12 Aari Ruben Selective enhancement of cannabis
BR112017014375A2 (pt) * 2014-07-18 2019-12-31 Medipath Inc composições e métodos para administração fisiológica usando canabidiol.
CN105342984A (zh) * 2014-08-21 2016-02-24 中国人民解放军总医院 一种用于治疗急性胰腺炎的可注射温敏凝胶制剂
US10398776B1 (en) * 2014-11-03 2019-09-03 Essential Green Goodness LLC Phonophoretic cannabidiol composition and transdermal delivery system
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10350165B2 (en) * 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
US10973584B2 (en) 2015-01-19 2021-04-13 Bard Access Systems, Inc. Device and method for vascular access
US20160250270A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US10716766B2 (en) 2015-03-02 2020-07-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids
WO2016210325A1 (en) 2015-06-26 2016-12-29 C.R. Bard, Inc. Connector interface for ecg-based catheter positioning system
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
US20180296521A1 (en) * 2015-10-16 2018-10-18 Scythian Biosciences Inc. Methods and compositions for treating gastrointestinal inflammation
US11000207B2 (en) 2016-01-29 2021-05-11 C. R. Bard, Inc. Multiple coil system for tracking a medical device
KR102202133B1 (ko) * 2016-01-29 2021-01-14 더 유니버시티 오브 미시시피 생물학적으로 활성인 칸나비디올 유사체
WO2017160923A1 (en) * 2016-03-15 2017-09-21 Royal Oil Colorado Llc Formulations of argan oil and cannabidiol
US10251825B2 (en) * 2016-07-29 2019-04-09 Iryna Kravchenko Composition with insect repellent activity
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
BR112019003815A2 (pt) 2016-08-29 2019-05-21 Canopy Growth Corporation composições solúveis em água compreendendo canabinoides purificados
CA3081755A1 (en) * 2016-11-07 2018-05-11 Avidas Pharmaceuticals Llc Therapeutic cannabinoid formulations and methods for their use
RU2660353C2 (ru) * 2016-12-02 2018-07-05 Тритек Биофармасьютикалз Ко., Лтд. Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5
US11147777B1 (en) 2017-06-16 2021-10-19 Charlotte's Web, Inc. Methods and formulations for efficacious pain relief by transdermal delivery of cannabidiol
AU2018318425A1 (en) * 2017-08-14 2020-02-27 Zynerba Pharmaceuticals, Inc. Methods of treatment of osteoarthritis with transdermal cannabidiol gel
BR112020004947A2 (pt) * 2017-09-19 2020-09-15 Zynerba Pharmaceuticals, Inc. canabidiol transdérmico sintético para o tratamento de epilepsia focal em adultos
BR112020005918A2 (pt) 2017-09-28 2020-10-06 Zynerba Pharmaceuticals, Inc. tratamento da síndrome do x frágil com canabidiol
US20190110981A1 (en) * 2017-10-17 2019-04-18 Life Tech Global, Llc Cannabinoid Patch
US20190125693A1 (en) * 2017-10-26 2019-05-02 Brandon Jones Kinesiology tape having cannabis-derived compounds
US10821084B2 (en) * 2018-01-31 2020-11-03 Remy Biosciences, Inc. Dihydromyricetin compositions
CN111989120A (zh) * 2018-04-13 2020-11-24 Healx有限公司 用于脆性x综合征的试剂盒、组合物和组合疗法
US11504416B2 (en) 2018-09-04 2022-11-22 Paw Power, Inc. Formulation with cannabinoids
EP3852622A1 (en) 2018-10-16 2021-07-28 Bard Access Systems, Inc. Safety-equipped connection systems and methods thereof for establishing electrical connections
US20220183999A1 (en) * 2019-04-05 2022-06-16 Sorrento Therapeutics, Inc. Cannabidiol Pharmaceutical Compositions
US20220378718A1 (en) 2019-05-28 2022-12-01 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
EP3975703A4 (en) * 2019-05-28 2023-07-12 Tech Swerve LLC PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USE
CA3145109A1 (en) * 2019-06-24 2020-12-30 Diverse Biotech, Inc. Cannabinoid conjugate molecules
EP3986389A4 (en) * 2019-06-24 2023-10-11 Diverse Biotech, Inc. CANNABINOID CONJUGATE MOLECULES
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
EP3994114A4 (en) * 2019-07-04 2023-08-16 Canopy Growth Corporation CANNABINOID DERIVATIVES
WO2021016612A1 (en) * 2019-07-25 2021-01-28 Hempvana, Llc Medication coated with hemp or other cannabinoid
CA3154135A1 (en) 2019-09-16 2021-03-25 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
AU2020361741A1 (en) * 2019-10-11 2022-04-07 Pike Therapeutics Inc. Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders
MX2022004258A (es) * 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
WO2021077111A1 (en) * 2019-10-17 2021-04-22 Aquavit Pharmaceuticals, Inc. Compositions and methods for delivering cannabinoids using microneedle devices to the skin
US20210177740A1 (en) * 2019-12-11 2021-06-17 Joel Studin Transpore delivery of cannabinoid and uses thereof
US20210244680A1 (en) * 2020-02-10 2021-08-12 Ghassan S. Kassab Wearable liposomal cannabidiol transdermal patch
US11202753B1 (en) 2020-03-06 2021-12-21 Aquavit Pharmaceuticals, Inc. Systems and methods for generating immune responses in subjects using microchannel delivery devices
WO2021228150A1 (zh) * 2020-05-13 2021-11-18 成都百裕制药股份有限公司 大麻素衍生物及其制备方法和在医药上的应用
CN116075296A (zh) * 2020-07-01 2023-05-05 长矛治疗股份有限公司 用于治疗多发性硬化症的透皮药物制剂
CN111789809A (zh) * 2020-08-05 2020-10-20 云南玉麻生物科技有限公司 大麻提取物透皮装置及其制备方法
GB202012836D0 (en) * 2020-08-17 2020-09-30 Futura Medical Developments Ltd Topical composition
AU2021328741A1 (en) * 2020-08-17 2023-02-02 Pike Therapeutics, Inc. Pharmaceutical compositions and methods for treating Parkinson's disease
CN112315896A (zh) * 2020-11-04 2021-02-05 深圳前海鹰岗生物科技有限公司 一种治疗痛风急性发作的聚合物微针及其制备方法
CN112279786B (zh) * 2020-11-23 2023-05-09 汤文建 一种大麻二酚氨基甲酸酯类化合物、药物制剂及制备方法与应用
CN114588131B (zh) * 2020-12-03 2024-03-08 汉义生物科技（北京）有限公司 一种大麻素的微针制剂及其制备方法和应用
WO2022118303A1 (en) * 2020-12-03 2022-06-09 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations comprising cbd or thc for the treatment of cancer
CN113087661B (zh) * 2021-03-24 2022-09-06 福建省中科生物股份有限公司 一种2’，6’-双吡啶取代大麻二酚醚类化合物及其制备方法和用途
WO2022212936A1 (en) * 2021-04-03 2022-10-06 Integrative Therapy Discovery Lab S.R.L. Methods and compounds of cannabidiol, melatonin and akba for treating pancreatic cancer
TW202304857A (zh) * 2021-04-07 2023-02-01 加拿大商美蒂普爾製藥公司 內生性大麻素系統靶向前驅藥及其治療用途
JP2024514843A (ja) * 2021-04-08 2024-04-03 パイク セラピューティクス インコーポレイテッド 発作性疾患を治療するための医薬組成物及び方法
CN117460503A (zh) * 2021-04-12 2024-01-26 长矛治疗股份有限公司 大麻二酚的透皮递送
US20220401355A1 (en) * 2021-05-13 2022-12-22 University Of Washington Transdural Drug Delivery System
EP4376893A2 (en) * 2021-07-29 2024-06-05 Emory University Phosphate prodrugs of cannabinoids
US20230059204A1 (en) * 2021-08-03 2023-02-23 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
CN113735709B (zh) * 2021-09-17 2022-03-18 中国农业科学院农产品加工研究所 一种大麻二酚-2-丁酸酯及其应用
AU2022360412A1 (en) * 2021-10-07 2024-02-29 Indorama Ventures Oxides Llc Alkoxylation of cannabidiol & other cannabinoids
CN116253700A (zh) * 2021-12-10 2023-06-13 德义制药有限公司 一种大麻二酚衍生物及其制备方法和应用
CN114225033B (zh) * 2021-12-23 2023-10-27 中纳科(南京)生物科技有限公司 前置空泡型大麻脂溶性活性物可溶微针及制备方法和应用
US11660348B1 (en) 2022-02-01 2023-05-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
WO2023150057A1 (en) * 2022-02-01 2023-08-10 Akos Biosciences, Inc. Cannabinoid conjugate molecules
US11883499B2 (en) 2022-02-01 2024-01-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
CN114832226B (zh) * 2022-05-10 2023-12-01 中国标准化研究院 一种抗抑郁助眠自溶性微针贴片及制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US325919A (en) 1885-09-08 Grain scouring and cleaning machine
US3216301A (en) 1964-01-27 1965-11-09 Bevis Ind Inc Edge trimming apparatus
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US20020111377A1 (en) * 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
US20080008745A1 (en) 2006-06-21 2008-01-10 University Of Kentucky Research Foundation Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and bis(hydroxy-methyl)propionyl-3-0 ester naltrexone using microneedles
ES2549115T3 (es) 2006-09-22 2015-10-23 Zynerba Pharmaceuticals, Inc. Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos
WO2008127459A1 (en) * 2007-04-16 2008-10-23 Blum Richard S Pharmacological treatment of psoriasis
CA2694325C (en) * 2007-07-30 2015-09-22 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
JP5559054B2 (ja) * 2007-09-28 2014-07-23 ザ クイーンズ ユニヴァーシティ オブ ベルファスト 送達装置および方法
US20110052694A1 (en) * 2009-08-31 2011-03-03 Alltranz Inc. Use of cannabidiol prodrugs in topical and transdermal administration with microneedles

Also Published As

Publication number Publication date
PT2473475T (pt) 2017-08-02
LT2473475T (lt) 2017-08-10
CA2772634C (en) 2017-11-21
JP2013503206A (ja) 2013-01-31
US20150197484A1 (en) 2015-07-16
US20110052694A1 (en) 2011-03-03
ES2635084T3 (es) 2017-10-02
WO2011026144A1 (en) 2011-03-03
US9533942B2 (en) 2017-01-03
HUE034235T2 (en) 2018-02-28
EP2473475A1 (en) 2012-07-11
SI2473475T1 (sl) 2017-10-30
CA2772634A1 (en) 2011-03-03
USRE47885E1 (en) 2020-03-03
CY1119059T1 (el) 2018-01-10
DK2473475T3 (en) 2017-06-26
PL2473475T3 (pl) 2018-02-28
EP2473475B1 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
HRP20171236T1 (hr) Upotreba prolijekova kanabidiola u topičkoj i transdermalnoj primjeni s mikroiglama
Eckenfels et al. Prostaglandins, oxygen tension and smooth muscle tone
ES2581574T3 (es) Sistema terapéutico transdérmico para la administración del principio activo buprenorfina
JP2008531693A5 (hr)
AR071366A1 (es) Composiciones que comprenden drogas debilmente basicas y formas de dosificacion de liberacion controlada. metodo de preparacion.
ES2575994T3 (es) Sistema y procedimiento para preparar, aplicar y retirar un revestimiento superior para gráficos despegables
CA2687722A1 (en) Modified release solid or semi-solid dosage forms
ES2210754T3 (es) Combinacion de analgesicos.
WO2008069283A1 (ja) 外用医薬組成物及び貼付剤
JP2016522792A5 (hr)
US20190240167A1 (en) Two-layer topical therapeutic system
AR083018A1 (es) Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden
JP2019521116A5 (hr)
BR112022010435A2 (pt) Camada-suporte solúvel para filme fino oral (otf)
CN115120577B (zh) 一种含有双氯芬酸的凝胶贴膏及其制备方法
Furuishi et al. Formulation design and evaluation of a transdermal drug delivery system containing a novel eptazocine salt with the Eudragit® E adhesive
RU2017129893A (ru) Фармацевтическая композиция для местного применения
Ren et al. Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation
JP2010510194A5 (hr)
JP5721231B2 (ja) アイソトープ標識２−アリールプロピオン酸類及びその製造方法、並びに陽電子放射断層画像撮像用分子プローブ及びそれを用いたシクロオキシゲナーゼ等のイメージング方法
ES2655885T3 (es) Uso de ácidos boswélicos para la profilaxis y/o tratamiento de daños y/o inflamación de los islotes de Langerhans
Jilani et al. Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis
Maroof et al. Flurbiprofen: a potent pain reliever
CA2543497A1 (en) Controlled release analgesic suspensions
JP2018537503A5 (hr)